Employed in the treatment of inflammatory diseases, and especially autoimmune diseases, glucocorticoids such as cortisone can unfortunately have significant side effects. To limit these, a team of researchers at the Institut Galien Paris-Sud (CNRS/Université Paris-Sud) has developed nanoparticles that allow these therapeutics to be transported to the inflammation site. However, because of their highly crystalline nature and their poor water solubility, encapsulating them is difficult.
The team has now overcome this problem by developing a new formula based on dexamethasone palmitate, a synthetic glucocorticoid, stabilized by nanoparticles, and tested it, in collaboration with researchers from Inserm, on arthritic mice. The drug passively accumulates in arthritic joints and leads to a remission of the disease and joint structure recovery at a low dose of just 1 mg/kg of dexamethasone without any adverse effects. The nanoparticles thus show promise for treating inflammation in rheumatoid arthritis and could prevent the disease from progressing, especially when inflammation is important. The research, which has been published in the Journal of Controlled Release, could be extended to other glucocorticoids.
Reference: Mathilde Lorscheider, Nicolas Tsapis, Mujeeb ur-Rehman, Françoise Gaudin, Ivana Stolfa, Sonia Abreu, Simona Mura, Pierre Chaminade, Marion Espeli, Elias Fattal
Dexamethasone palmitate nanoparticles: An efficient treatment for rheumatoid arthritis, Journal of Controlled Release
For a news story on this publication, please email firstname.lastname@example.org